지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
약년자 폐암의 임상적 연구
Tuberculosis and Respiratory Diseases
2000 .01
Lived Experience among Patients Newly Diagnosed with Lung Adenocarcinoma Stage IV within One Year
Asian Pacific journal of cancer prevention : APJCP
2015 .01
Epidemiology of Lung Cancer in Korea: Recent Trends
Tuberculosis and Respiratory Diseases
2016 .01
Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment
Cancer Research and Treatment
2019 .01
45세 이하 약년자 폐암 94례의 임상적 특징
Tuberculosis and Respiratory Diseases
2002 .01
Lung Cancer in Korea
Cancer Research and Treatment
2002 .01
약년자 폐암 환자의 임상적 특성
Tuberculosis and Respiratory Diseases
2001 .01
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Cancer Research and Treatment
2019 .01
Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
Annals of Laboratory Medicine
2017 .01
The Incidence Rate and Severity of Orthotopic Lung Cancer in an Animal Model Depends on the Number of A549 Cells and Transplantation Period
Laboratory Animal Research
2010 .12
서서히 자라는 폐암의 임상적 특성: 6증례 평가
Tuberculosis and Respiratory Diseases
2010 .01
폐암(Lung Cancer)
보건세계
1999 .01
76세 이상 노령자 폐암에서의 임상적 특징
대한내과학회지
2012 .01
폐암의 조기진단 방법에 관한 연구
Tuberculosis and Respiratory Diseases
1991 .01
Risk Factors for Lung Cancer Mortality in a Referral Center
Asian Pacific journal of cancer prevention : APJCP
2016 .01
Early Detection of Lung Cancer Risk Using Data Mining
Asian Pacific journal of cancer prevention : APJCP
2013 .01
Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Cancer Research and Treatment
2018 .01
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
영남의대학술지
2017 .01
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
Journal of Yeungnam Medical Science
2017 .01
0